Cromolerg

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cromolerg

What is Cromolerg?

Cromolerg is an ophthalmic medication used to manage allergic conditions affecting the eyes. It belongs to a class of drugs known as mast cell stabilizers. Unlike medications that treat symptoms after they have already appeared, this solution works by preventing the underlying biological processes that lead to allergic inflammation.

Mechanism of Action

The active ingredient in Cromolerg acts on specific immune cells called mast cells, which are found in the mucosal tissues of the eye. When an individual with allergies is exposed to triggers—such as pollen, pet dander, or dust mites—these mast cells typically rupture and release inflammatory substances, including histamine.

Cromolerg works by stabilizing the membrane of these mast cells. By preventing the release of histamine and other chemical mediators, the medication helps reduce the characteristic signs of an allergic reaction, such as redness, itching, and swelling.

Primary Uses

Cromolerg is primarily indicated for the treatment of various forms of allergic conjunctivitis, including:

  • Seasonal Allergic Conjunctivitis: Allergic reactions that occur at specific times of the year, often linked to outdoor allergens like grass or tree pollen.
  • Vernal Keratoconjunctivitis: A more chronic and severe form of seasonal inflammation that often affects children and young adults.
  • Giant Papillary Conjunctivitis: An inflammatory condition sometimes associated with the use of contact lenses or ocular prosthetics.

Because of its preventative nature, the medication is most effective when used consistently to maintain a stable environment for the ocular surface during periods of high allergen exposure.

Regulatory References

  1. Cromolyn Sodium - StatPearls - NCBI Bookshelf

What side effects are possible with Cromolerg?

Possible Side Effects and Safety Information

The safety profile of Sodium Cromoglycate (Cromolerg) is predominantly characterized by localized reactions at the site of administration, reflecting its minimal systemic absorption as a mast cell stabilizer. The most commonly documented adverse reactions are those related to temporary irritation and discomfort.

Officially Documented Adverse Reactions by Frequency

Frequency Classification Key Adverse Reaction Categories
Common Local irritation, transient stinging, burning, sneezing, cough, throat irritation, headache.
Uncommon Hypersensitivity reactions (e.g., rash, pruritus).
Not Known/Rare Anaphylaxis, angioedema, severe bronchospasm.

Safety Considerations and Restrictions

The most frequent effects fall under the Eye Disorders or Respiratory, Thoracic and Mediastinal Disorders System Organ Classes (SOC), and are typically transient, occurring immediately upon administration. Serious adverse reactions, such as anaphylaxis and severe bronchospasm (associated with the inhalation form), are classified as rare but clinically significant manifestations of immune system disorders.

Safety Limitations

Administration is contraindicated in individuals with a known hypersensitivity to Sodium Cromoglycate or any non-active ingredients in the formulation. Due to the drug's minimal systemic absorption, official regulatory documentation generally does not mandate specific safety statements or dose modifications for populations with renal or hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Cromolerg (Sodium Cromoglycate) is defined by its low systemic absorption, with regulatory documents stating that no toxic effects have been reported following an overdose. Furthermore, there are no documented cases of overdosage with the drug. Severe or life-threatening outcomes are not explicitly listed in the official overdose sections, reflecting the low risk of systemic toxicity.

Required Emergency Actions

Situation Official Regulatory Requirement
Suspected Overdose Seek immediate medical attention for management.
Guidance Contact your regional poison control centre for procedural guidance.

Management and Clinical Monitoring

The officially described management strategy is constrained by the fact that no specific antidote is mentioned in the prescribing information. Treatment should be symptomatic to address any observed effects. Following any suspected overdosage, medical observation is recommended. In cases of excessive local administration, regulatory guidance may describe procedures such as copiously washing the area with sterile physiologic serum. Accidental ingestion of the solution requires medical supervision only.

Therapeutic Uses of Cromolerg

What Cromolerg Treats: Main Uses and Benefits

Cromolerg, containing Sodium Cromoglycate, is primarily used to help manage the symptomatic discomfort of various allergic conditions. Its role is relevant for easing symptoms across the upper airways, lower airways, and the eyes. This preparation is used in clinical settings marked by recurrent or episodic manifestations.

It is commonly used for conditions such as allergic rhinitis (seasonal and perennial), allergic conjunctivitis (including vernal keratitis), and the management of conditions such as mild to moderate bronchial asthma.

The medication is applied across therapeutic domains where additional symptomatic support is needed, helping to address symptom clusters that may become disruptive, including sneezing, nasal congestion, eye itching, and breathing difficulties caused by specific triggers. The key therapeutic benefit contributes to maintaining a sense of stability and assists with easing the overall symptom burden.

“The preparation is used to support the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort.”

Quick Fact: Relief for Localized Allergic Symptoms

Symptom Domain Conditions Managed Primary Benefit
Nasal Seasonal and perennial rhinitis Assists with maintaining clear nasal passages.
Ocular Allergic conjunctivitis Supports management of eye itching and tearing.
Pulmonary Mild asthma exacerbations Is relevant for easing breathing difficulties after exposure to triggers.

Eligibility and Restrictions for Use

Official Eligibility for Cromolerg (Sodium Cromoglycate)

Eligibility for Cromolerg is defined by official regulatory labeling across specific patient populations and conditions. The medicine is primarily approved for use in adults and adolescents across its various forms (ophthalmic, nasal, inhalation, and oral).

Absolute Contraindications

Cromolerg is strictly contraindicated for any patient with a known hypersensitivity or allergy to Sodium Cromoglycate or any other component in the product's formulation.

Age and Conditional Restrictions

Eligibility in pediatric patients is age-dependent and form-specific; for instance, the inhalation solution is generally not established for safety and effectiveness in children below the age of 2 years. The medicine is strictly for prophylactic use and must not be used to treat acute episodes of asthma or severe allergic reactions.

Special Population Cautions

Use in patients with decreased renal (kidney) or hepatic (liver) function requires caution, as regulators advise a potential dose decrease for the oral solution. For pregnancy (FDA Category B), use is restricted to circumstances where it is clearly needed. Use during lactation should be approached with caution as excretion into human milk is unknown.

What should I know about interactions with other medicines?

The official interaction profile for Cromolerg (Sodium Cromoglycate) is primarily defined by its very low systemic absorption when applied topically as an ophthalmic, nasal, or nebulizer solution. This minimal exposure means that no clinically significant systemic drug-drug interactions are known or formally documented in regulatory prescribing information.

Documented Interaction Profile

Systemic Drug-Drug Interactions: No specific interactions involving CYP-mediated metabolism or drug transporters have been identified or documented. This pharmacological characteristic confirms that corticosteroids and other commonly used allergy medications may be administered concomitantly.

Interactions with Products and Administration Timing: The main restriction is a physical-chemical constraint related to the ophthalmic solution. Patients using soft (hydrophilic) contact lenses must remove them before instillation and wait at least 15 minutes before reinserting them. This mandatory timing separation is due to the potential for the preservative, such as Benzalkonium chloride, to be absorbed by the lens material. No specific interactions with food, alcohol, or herbal products are documented for the topical formulations.

Population-Specific Cautions: Due to the drug’s clearance pathways through the kidneys and liver, official labels advise that consideration should be given to decreasing the dosage in patients with known impaired renal or hepatic function. Hypersensitivity to Sodium Cromoglycate or any excipients constitutes a formal contraindication.

Mechanism of Action

Cromolerg functions through a selective interaction with an unknown receptor on the mast cell membrane, which results in the inhibition of inflammatory mediator release. This inhibitory action results in the maintenance of mast cell membrane integrity.

The compound modulates the mast cell degranulation pathway by blocking a chloride channel and interfering with the calcium-dependent release of stored granules. This reduces calcium ion influx necessary for the degranulation process.

The compound’s mechanism is confined to the inhibition of mast cell degranulation and does not appear to involve H1 receptor antagonism. The compound exhibits an extremely low IC50 for this specific inhibitory effect.

Dosage and Administration Information

Cromolerg (Sodium Cromoglycate) is administered using four distinct routes, each governing a specific dosing regimen and usage protocol. The administration methods include inhalation (via nebulizer solution), topical ophthalmic (eye drops), topical intranasal (nasal spray), and oral (as a diluted concentrate solution) for specialized uses.

The overall usage protocol is defined by a fixed frequency schedule, requiring the medicine to be administered multiple times daily—typically four times a day (QID) at regular intervals—to sustain the required usage pattern.

Route of Administration Standard Adult Maintenance Dose Frequency/Timing Constraint
Inhalation 20 mg (1 vial) via power-driven nebulizer. QID at regular intervals.
Ophthalmic 1 to 2 drops per eye. Up to 4-6 times daily.
Oral Solution 200 mg (2 ampules) initial dose. QID, strictly 30 minutes before meals and at bedtime.

For the oral solution, preparation involves squeezing the ampule's contents into a glass of water, stirring, and consuming the full liquid. Pediatric dosing for the oral solution (ages 2-12) is 100 mg QID. For all forms, administration must be continuous for the full duration of the allergen exposure period, as maximum benefit may not be evident until several weeks of consistent use. The inhalation form can also be administered as a single dose 10–60 minutes prior to exercise or exposure.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cromolerg


Evidence for Use in Allergic Rhinitis (Nasal Allergies)

Research examining the use of the nasal spray formulation was conducted in various settings, primarily involving short-term Randomized Controlled Trials (RCTs). These studies were applied in research exploring how symptoms change over time in both adults and children with seasonal or perennial allergic rhinitis. Researchers examined outcomes related to physical discomfort such as sneezing and nasal congestion, along with the patient-reported use of other symptomatic medications.

The findings describe patterns observed in the studies where studies described measurements of different short-term symptom outcomes compared to a placebo comparator. Despite this evidence base, certainty remains low when comparing these findings to research available for commonly used allergy medications. Therefore, the comparative evidence is lacking for a full picture against current treatment standards, and follow-up durations were limited in many key studies.


Evidence for Use in Allergic Conjunctivitis (Eye Allergies)

The ophthalmic solution was studied for conditions characterized by fluctuating or episodic manifestations of eye allergies. The core evidence comes from double-masked controlled trials and systematic reviews which monitored outcomes capturing phases of heightened symptom activity. These studies included both adults and children and focused on patient-reported outcomes describing perceived discomfort such as itching, tearing, and redness.

Studies report how symptoms evolved in the observed populations over intervals lasting up to several weeks. Findings from the combined research described that participants reported different measurements of control or perceived change compared to the control groups. However, the available research is predominantly short-term, meaning long-term study findings are not fully established for managing chronic or perennial forms of eye allergies. The evidence quality varies across studies, and the high variability in outcomes reported indicates subgroup findings are uncertain.

Key Studies & References Cromolyn Sodium Drug Information (MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Cromolerg (FAQ)


Q: What is the main difference between Cromolerg and other anti-allergy medications?

A: Cromolerg is classified as a mast cell stabilizer. Regulatory documents state that its function is described as preventing allergic symptoms by stabilizing mast cells, which inhibits the release of inflammatory chemicals like histamine. This is a different approach than antihistamines, which typically work by blocking the action of histamine after it has already been released.


Q: How quickly does Cromolerg start to work?

A: Studies and official information indicate that Cromolerg is primarily a preventive medication. Consistent daily use is typically employed, and maximum effects may take between one and four weeks to become evident. For acute prevention, such as before exercise, it is administered 10 to 60 minutes prior to the activity.


Q: Is Cromolerg considered safe for older adults?

A: Clinical experience in older adults is limited, but official documents indicate the medicine has not shown evidence of different problems than in younger adults. Dosage selection may need to be cautious due to the possibility of decreased kidney, liver, or heart function, which is more frequent in this population.


Q: What is the recommended period of use for Cromolerg?

A: The official product information advises that therapy should be continued throughout the full period of allergen exposure, such as the entire season. For over-the-counter (OTC) nasal use, regulatory guidance advises that consultation with a healthcare provider is appropriate if the product is used for longer than 12 consecutive weeks.


Q: Why is Cromolerg sometimes prescribed over other allergy drugs?

A: Cromolerg acts primarily locally at the site of application (such as the nose or eyes) and is minimally absorbed into the rest of the body. This minimal systemic absorption is a characteristic of the drug, resulting in a profile that is noted for its low risk of certain systemic side effects.


Q: What is the role of Cromolerg in managing chronic allergy symptoms?

A: The core role of Cromolerg is prophylactic (preventive). Evidence indicates it is used regularly on a continuous basis, rather than only during active flare-ups, to prevent chronic allergy symptoms from developing. Maximum benefit may not be seen until several weeks of consistent treatment have passed.


Q: Do you feel sleepy after taking Cromolerg?

A: Drowsiness or sedation is not explicitly listed as a common side effect. However, official adverse event listings do include other central nervous system effects such as dizziness, headache, and insomnia (trouble sleeping).


Q: Is it possible for Cromolerg to cause stomach upset?

A: Gastrointestinal (GI) side effects are documented, especially with the oral solution and capsules used for systemic conditions. These reported effects can include diarrhea, nausea, vomiting, and abdominal pain.


Q: What is Cromolerg used for besides allergies?

A: In addition to various allergic conditions, official documents indicate that the oral formulation is approved for the management of systemic mastocytosis and certain cases of food allergies. The inhalation form is also documented for preventing exercise-induced bronchospasm.


Q: How long does the effect of one dose of Cromolerg usually last?

A: The drug's administration schedule involves administration four times daily (QID) at regular intervals. This dosing protocol suggests that the therapeutic effect of a single dose generally lasts for approximately six hours.


Q: Why do some people say Cromolerg stopped working for them after a while?

A: The official product information does not directly discuss a loss of efficacy over time. However, the scientific concept of a rapidly decreasing response (tachyphylaxis) is mentioned in pharmacological literature, though its clinical relevance in standard patient use is not definitively established.


Q: Is Cromolerg available without a prescription?

A: Official drug facts state that the nasal spray formulation (for allergic rhinitis) is widely available as an Over-the-Counter (OTC), non-prescription medicine in many regions. However, other forms, such as the oral and nebulizer solutions, still require a prescription.


Q: Does Cromolerg affect blood pressure?

A: Regulatory reports list potential side effects related to the heart, such as palpitations (racing heart) and tachycardia (fast heart rate). The regulatory information advises caution when the medication is used by individuals with a history of heart conditions.


Q: Is it normal to feel a bit restless after using Cromolerg?

A: The official adverse reaction reports list central nervous system effects that may be related to feelings of restlessness. These reported effects include irritability, anxiety, and insomnia (trouble sleeping).


Q: Does Cromolerg require any special monitoring while being used?

A: Regulatory information advises monitoring for certain issues. Patients are typically monitored for signs of allergic reactions (including anaphylaxis), the development of bronchospasm (with the inhaled form), and changes in gastrointestinal symptoms if the systemic oral form is being used.


Q: Why is Cromolerg classified the way it is?

A: Cromolerg is classified as a mast cell stabilizer because its sole mechanism is to prevent mast cells from releasing inflammatory substances into the body. It achieves this by inhibiting the degranulation process, which prevents allergic symptoms.


Q: Is there a generic version of Cromolerg available?

A: Official drug information indicates that the active ingredient, Sodium Cromoglycate (Cromolyn Sodium), is available in generic form for several approved preparations, including the nasal spray and ophthalmic solution.


Q: Is Cromolerg suitable for people with heart conditions?

A: Official product labeling indicates that caution is advised for individuals with a history of cardiac arrhythmias (irregular heartbeats). Monitoring is generally advised for those with pre-existing heart conditions.


Q: Can I stop taking Cromolerg suddenly?

A: Regulatory guidance indicates that symptoms of the treated condition may recur or worsen if the medication is abruptly reduced or discontinued.


Q: Does Cromolerg cause a dry mouth?

A: Dry mouth is not explicitly listed as a common systemic side effect. However, local side effects, such as mouth and throat irritation and dysphagia (difficulty swallowing), have been reported with the use of the oral and inhaled formulations.

How should Cromolerg be stored and disposed of?

Storage and Disposal of Cromolyn Sodium

To ensure product stability, Cromolyn Sodium must be stored according to specific regulatory requirements. The medicine must be kept at Controlled Room Temperature, generally defined as a range between 15^circ to 30^circC (59^circ to 86^circF). It is mandatory to protect the solution from light and strictly do not freeze the product. The container must remain tightly closed and stored in its original carton or foil pouch until use.

Stability and Handling Constraints

Constraint Official Requirement
Freezing Must be avoided
Integrity Do not use if discolored or contains a precipitate
Disposal Discard any remaining contents after the prescribed treatment period

All forms of the medicine must be kept out of the reach of children. Unused or expired contents should be discarded according to official instructions, which typically recommend not keeping outdated medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cromolerg found in:

A-Z Index: